No Data
Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393) Might Not Be As Mispriced As It Looks
Tianjin Lisheng Pharmaceutical (002393.SZ): has repurchased a total of 2.37% of its shares.
On January 7, Gelonghui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) announced that as of January 7, 2025, the company repurchased shares through a dedicated securities account for Share Buyback via centralized bidding, with a total of 6,104,940 shares repurchased, accounting for 2.37% of the company's current total share capital. The highest Fill Price was 18.50 yuan per share, the lowest Fill Price was 17.28 yuan per share, and the total transaction amount was 0.109 billion yuan (excluding transaction fees).
Overview of the lifting of restrictions on A-shares | December 30
According to Zhichun Financial APP, on December 30, a total of 37 listed companies had their restricted shares unlocked, with a total market value of approximately 12.254 billion yuan. Today's specific situation of the restricted shares unlocked is as follows: Stock Abbreviation Stock Code Restricted Stock Type Number of Stocks Unlocked Henan Yuneng Holdings 001896 Placement of A-shares for original shareholders 0.205 billion Datang Telecom Technology 600198 Placement of A-shares for original shareholders 0.428 billion China National Software & Service 600536 Stock-based Incentive restricted circulation 0.7513 million Xiamen Tungsten 600549 Stock-based Incentive restricted circulation 3.6369 million Yueyang Forest & Paper 600963 Stock-based Incentive restricted circulation 0.27 million
Tianjin Development Subsidiary to Repurchase Shares, Grant Shares Under Share Award Scheme
Tianjin Lisheng Pharmaceutical (002393.SZ): Plans to launch the 2024 restricted stock incentive plan.
On December 20, Gelonghui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) announced the 2024 Stock-based Incentive plan, which proposes to grant up to 7,210,000 shares of restricted stocks to the incentivized individuals, accounting for approximately 2.80% of the total share capital of the company, which is 257,942,988 shares. Among these, an initial grant of 5,770,000 shares of restricted stocks will be made, accounting for 80.03% of the total restricted stocks; about 1,440,000 shares of restricted stocks will be reserved, accounting for 19.97% of the total restricted stocks. After the implementation of this incentive plan, the company's equity incentive plan will remain effective throughout the entire period.
Tianjin DEV (00882.HK) subsidiary Tianjin Lisheng Pharmaceutical plans to repurchase shares and adopt a stock incentive plan.
On December 20, Grizzly Holdings announced that TIANJIN DEV (00882.HK) has approved a share buyback plan at the Board of Directors of Tianjin Lisheng Pharmaceutical (a non-wholly-owned subsidiary indirectly listed on the Shenzhen Stock Exchange) on December 20, 2024. Accordingly, starting from December 21, 2024, within a period of twelve months, Tianjin Lisheng Pharmaceutical is allowed to repurchase its ordinary shares through centralized bidding on the Shenzhen Stock Exchange at the current market price, with a total amount not less than 76.5 million yuan and not exceeding 0.153 billion yuan. The Board of Directors of Tianjin Lisheng Pharmaceutical recommends that this be approved by its Shareholders at the Shareholders' meeting.
Investors Don't See Light At End Of Tianjin Lisheng Pharmaceutical Co.,Ltd.'s (SZSE:002393) Tunnel And Push Stock Down 25%
